Trodelvy patent?

When Does Trodelvy Patent Expiry Occur?

Trodelvy (sacituzumab govitecan-hziy) is a cancer treatment medication developed by Immunomedics and licensed to Gilead Sciences. It is used for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+, HER2-) metastatic breast cancer, metastatic urothelial cancer, and triple-negative breast cancer.

Who Holds the Current Patent?

As of our knowledge cutoff, Gilead Sciences holds the global rights to Trodelvy.

What Is the Current Patent Expiry Status?

According to [DrugPatentWatch.com (1)], the Trodelvy US patent (US 10,555,987) is set to expire on December 16, 2031. [1]

What Are the Consequences of Patent Expiry?

When the patent expires, other companies can potentially develop and manufacture generic versions of Trodelvy, which may lead to increased competition in the market and reduced prices for consumers.

Is Generic Trodelvy Possible Before Patent Expiry?

Biosimilars or generic versions of Trodelvy must go through a rigorous approval process, which involves demonstrating comparable efficacy, safety, and quality to the original drug. Companies may begin the process of developing a biosimilar or generic Trodelvy shortly before or after patent expiry, but the exact timeline and availability depend on regulatory approvals.

What Are Users Asking About?

As patent expiry draws near, users may be searching for information about pricing, availability, and potential generic alternatives for Trodelvy.

References

[1] DrugPatentWatch.com: Trodelvy Patent Expiration Dates (Accessed December 2023) https://www.drugpatentwatch.com/patent-expiration-date/trodelvy-sacituzumab-govitecan-hziy